http://www.onclive.c...mia-case-study-
In the article above, Dr. Cortes leads a discussion among a panel of doctors regarding a hypothetical patient presenting with CML. What do these doctors do? It's a great read.
Case Study: Selecting a TKI treatment - doctor's perspective
Started by
scuba
, Apr 02 2016 07:22 AM
3 replies to this topic
#1
scuba
-
- Members
-
- 1,044 posts
Advanced Member
- LocationHouston, Texas
Posted 02 April 2016 - 07:22 AM
Diagnosed 11 May 2011 (100% FiSH, 155% PCR)
with b2a2 BCR-ABL fusion transcript coding for the 210kDa BCR-ABL protein
Sprycel: 20 mg per day - taken at lights out with Quercetin and/or Magnesium Taurate
6-8 grams Curcumin C3 complex.
2015 PCR: < 0.01% (M.D. Anderson scale)
2016 PCR: < 0.01% (M.D. Anderson scale)
March 2017 PCR: 0.01% (M.D. Anderson scale)
June 2017 PCR: "undetected"
September 2017 PCR: "undetected"
#2
Harper3994
-
- Members
-
- 56 posts
Advanced Member
- LocationTrinity, Florida
Posted 02 April 2016 - 08:31 AM
Thanks Scuba for giving us this link. So interesting and my doctor is on the panel.
#3
tiredblood
-
- Members
-
- 474 posts
Advanced Member
Posted 06 April 2016 - 11:12 PM
Cool, my doc is on the panel too.
#4
r06ue1
-
- Members
-
- 426 posts
Advanced Member
- LocationEarth, Solar System, Milky Way, Local Group, Virgo Supercluster, Laniakea
Posted 07 April 2016 - 08:25 AM
Strange that most of them lean towards nilotinib instead of dasatinib, I thought nilotinib had more issues with heart than dasatinib?
08/2015 Initial PCR: 66.392%
12/2015 PCR: 1.573%
03/2016 PCR: 0.153%
06/2016 PCR: 0.070%
09/2016 PCR: 0.052%
12/2016 PCR: 0.036%
03/2017 PCR: 0.029%
06/2017 PCR: 0.028%
09/2017 PCR: 0.025%
12/2017 PCR: 0.018%
Taking Imatinib 400 mg
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
